The skin's secret script: fingerprints of CD34 and the dolphin dance of Schwann cells
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20253401Keywords:
Segmental neurofibromatosis, Spindle cell tumour, S100, CD34, ImmunohistochemistryAbstract
Segmental neurofibromatosis (SNF), or Riccardi type V, is an uncommon mosaic variant of neurofibromatosis type 1, arising from postzygotic mutations in the NF1 gene. It reveals itself through dermatomally confined clusters of neurofibromas, usually in the absence of systemic features or family history. A 55-year-old woman presented with multiple, progressively enlarging papulonodular lesions localized to the left upper arm. Histopathological analysis demonstrated a non-encapsulated dermal spindle cell tumor with elongated, wavy, buckled nuclei-reminiscent of “diving dolphins”-set within a fibro-myxoid, mast cell-rich stroma. Immunohistochemistry further refined the picture: Schwann cells showed diffuse S100 positivity, while CD34 staining unveiled the delicate “fingerprint” pattern of dendritic fibroblasts. Taken together, these findings confirmed the diagnosis of neurofibroma. The segmental distribution and absence of systemic features established the diagnosis of SNF. The lesions were excised sequentially using elliptical incisions, leading to uneventful recovery and satisfactory cosmetic results. This case underscores the diagnostic value of correlating clinical distribution with distinctive microscopic clues. The dermatomal clustering of lesions, the evocative “diving dolphin” nuclei, and the CD34 fingerprint pattern together form a compelling diagnostic triad of SNF. Awareness of these features helps avoid misclassification among spindle cell tumours and ensures that management remains both accurate and tailored to patient needs.
Metrics
References
Sobjanek M, Dobosz-Kawałko M, Michajłowski I, Pęksa R, Nowicki R. Segmental neurofibromatosis. Postepy Dermatol Alergol. 2014;31(6):410-2. DOI: https://doi.org/10.5114/pdia.2014.40942
Gayathri A, Ramachandran R, Narasimhan M. Segmental neurofibromatosis with Lisch nodules. Med J Armed Forces India. 2023;79(3):356-9. DOI: https://doi.org/10.1016/j.mjafi.2020.11.021
Bajaj A. The Neural Pleonastics – Neurofibroma. J Clin Med Images. 2020;5(4):1-6.
Iswarya A, Vijayasankar P, Karthikeyan K, Sriram V. Segmental leiomyoma: a report of two cases. Turk J Dermatol. 2021;15(3):80-2. DOI: https://doi.org/10.4103/tjd.tjd_50_21
Englander L, Emer JJ, McClain D, Amin B, Turner RB. A rare case of multiple segmental eccrine spiradenomas. J Clin Aesthet Dermatol. 2011;4(4):38-44.
Bhabha FK, Magee J, Ng SY, Grills CE, Su J, Orchard D. Multiple clustered dermatofibroma presenting in a segmental distribution. Australas J Dermatol. 2016;57(1):e20-2. DOI: https://doi.org/10.1111/ajd.12257
Bosch F, Rosich L. The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize. Pharmacology. 2008;82(3):171-9. DOI: https://doi.org/10.1159/000149583
Hong SP, Ahn SK. Abundant eosinophil infiltration in a neurofibroma. Am J Dermatopathol. 2007;29(2):187-9. DOI: https://doi.org/10.1097/DAD.0b013e318033275e
Nagrani NS, Bhawan J. Histopathological variants of cutaneous neurofibroma: a compendious review. Dermatopathology (Basel). 2022;10(1):1-19. DOI: https://doi.org/10.3390/dermatopathology10010001
Yeh I, McCalmont TH. Distinguishing neurofibroma from desmoplastic melanoma: the value of the CD34 fingerprint. J Cutan Pathol. 2011;38(8):625-30. DOI: https://doi.org/10.1111/j.1600-0560.2011.01700.x
Park JY, Park H, Park N, Park J, Sung HJ, Lee S. Use of calretinin, CD56, and CD34 for differential diagnosis of schwannoma and neurofibroma. Korean J Pathol. 2011;45(1):30-5. DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.1.30
Ghosh PS, Ghosh D. Teaching NeuroImages: MRI “target sign” and neurofibromatosis type 1. Neurology. 2012;78(9):e63. DOI: https://doi.org/10.1212/WNL.0b013e318248df63
Klesse LJ, Jordan JT, Radtke HB, Rosser T, Schorry E, Ullrich N, et al. The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities. Oncologist. 2020;25(7):e1109-16. DOI: https://doi.org/10.1634/theoncologist.2020-0069